Search results for Alexion Pharmaceuticals

Alexion Beats Trade Secret Claims In Amyndas Suit

Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to...

Amylyx (AMLX) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSCo-Chief Executive Officer — Justin KleeCo-Chief Executive Officer — Joshua CohenChief Commer...

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

Biogen links up with Alloy platform to boost ASO drug development

The agreement allows Biogen to apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for...

<![CDATA[Angelini Pharma Enters $ 4.1 Billion Agreement to Acquire Catalyst Pharmaceuticals ]]>

FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111

FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

<![CDATA[Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava]]>

<![CDATA[Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement]...

Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical T...

SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovat...

With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’

Three weeks into taking on the role of Lexicon Pharmaceuticals CEO back in 2024, Michael Exton told Fierce the company close its commercial operations.

Axonics

Axonics Anonymous (not verified) Sun, 04/05/2026 - 17:00 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia

This announcement contains inside information CHESTNUT randomised, open-label, active-controlled trial demonstrated safety and tolerability of efzimfotase alfa in paediatric patie...

Axsome Drug’s FDA Approval Unlocks New Opportunity in Alzheimer’s Agitation

Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axso...

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme...

Blackstone Life Sciences (“BXLS”) today announced a $250 million investment in Anagram Therapeutics (“Anagram”), a clinical-stage private biopharmaceutical company dedicated to imp...

<![CDATA[Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics ]]>

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than pursue the phase 3 program envisaged before it acquir...

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

Axonics

Axonics Anonymous (not verified) Sat, 05/09/2026 - 08:22 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...